Tubulis
Key Facts
| Invested since | 2020 |
| Based in | Bavaria |
About the company
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication
Do you want to
know more about this company?
Tubulis in the news
Zum Artikel
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Zum Artikel
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
Zum Artikel
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
More startups from Life Sciences
Exit
c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either …
To the complete profileof c-LEcta
PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring …
To the complete profileof PreComb
Numaferm developed a platform technology for fast, scalable and cost-efficient production of peptides and proteins, with a focus on pepteins (PEPTides & protEINS) in the range of 30-500 amino acids. …
To the complete profileof NUMAFERM
Exit
cytena’s single-cell printer is a unique device for separating, sorting and handling of single biological cells. For the first time this method enables an automated, separation of single cells with …
To the complete profileof Cytena
IPO
Immunic Therapeutics is a clinical-stage biotech company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. Immunic, Inc. is headquartered in New York. …
To the complete profileof Immunic
Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in …
To the complete profileof Signatope
AdvanceCOR is a drug-developing biotech company which focuses on personalized medicine in cardiovascular diseases. We concentrate on innovative biologic drugs in acute vascular syndromes and have completed phase 2.
To the complete profileof AdvanceCOR
faCellitate develops patented polymeric surface coatings for plastic and glassware enabling 3-dimensional cell culture, amongst other uses. Initially, the technology was developed at the BASF research department for polymers. The …
To the complete profileof faCellitate
AudioCure Pharma is an innovative clinical-stage pharmaceutical company focused on developing treatments for audiological and neurological disorders with a high unmet medical need. Our small molecules have shown Proof-of-Principle in …
To the complete profileof AudioCure
Exit
The founders of Kumovis GmbH have set themselves the goal of enabling the additive production of plastic implants and are developing innovative 3D printers specifically for medical products. Kumovis focuses …
To the complete profileof Kumovis
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and …
To the complete profileof Nebula Biocides
Inovedis is developing a new surgical technique for rotator cuff ruptures based on a PEEK implant. This injury is by so far the most typical shoulder injury. The patented SINEFIX …
To the complete profileof Inovedis